Assay Development for Automated Clinical Immunoassay Analyzers
Automated clinical immunoassay analyzers are the backbone of the in vitro diagnostics (IVD) industry— and a critical driver in turning innovative assays into market-ready solutions. At Future Diagnostics, we specialize in IVD assay development and commercialization strategies, using our broad range of in-house automated immunoassay analyzers to accelerate your path to market.
Our state-of-the-art facility houses leading clinical immunoassay platforms, among others Abbott Alinity, Abbott Architect and Beckman Coulter DxI 600.
These analyzers allow us to work with both standard reagents and novel reagents under development, generating high-quality data that supports regulatory approval and successful diagnostic assay commercialization. This means faster, more reliable results for your project, reducing time-to-market and increasing your competitive advantage.
From Assay Concept to Commercialization
Looking to bring your novel diagnostic assay to market? Future Diagnostics helps you demonstrate performance with proof-of-concept experiments on industry-leading clinical immunoassay analyzers.
Our services include:
- Platform transfer studies (e.g., migrating assays from ELISA to automated immunoassay analyzers), ensuring your assay is compatible with high-throughput, automated systems used in clinical laboratories worldwide.
- Performance validation using real-world analyzer systems
- Strategic data generation to strengthen your commercialization pathway
With decades of expertise in IVD assay development, we provide the technical support and scientific insights needed to transition your assays from the lab to the global diagnostics market.
Comparison Studies on Clinical Immunoassay Analyzers
During IVD development, it is essential to compare results with established clinical methods. Future Diagnostics offers:
- Comparison studies with standard reagents on automated analyzers
- Pilot studies with novel reagents under development to assess their behaviour in automated systems
Our in-house analyzers enable robust comparison studies that validate assay performance, strengthen regulatory submissions, and accelerate commercialization timelines.
Get in touch with us
Get in touch with us to learn how our automated clinical immunoassay analyzers can support your IVD development.
